Japan’s drug pricing panel held its final round of industry hearings on December 10 as it heads toward the FY2026…
HOME > REGULATORY
REGULATORY
- MHLW to Show Detailed Steps to Foster Pharma Sector in November
October 21, 2015
- Patent Extension, Patent Linkage Rules in TPP Require No Rule Changes in Japan: MHLW Official
October 20, 2015
- 5 Members to Leave Chuikyo before Full-Fledged Debate Begins for 2016 Reform
October 20, 2015
- Govt to Reduce Stockpiles of Anti-Pandemic Flu Drugs
October 19, 2015
- PAFSC 1st Committee to Discuss Lexapro for Social Anxiety Disorder on Oct. 30
October 19, 2015
- AMED to Launch Project to Fund Orphan Drug Hopefuls
October 19, 2015
- AMED’s Joint Drug Discovery Project to See Match-Ups by the End of October: President Suematsu
October 16, 2015
- Chuikyo Subcommittee OKs 70% Threshold for DPC Incentive
October 16, 2015
- Additional Indication of Xeloda, Elplat to Be Reported to PAFSC’s 2nd Committee on Oct. 29
October 16, 2015
- High Unmet Medical Need for Lenalidomide: Council on Unapproved Drugs
October 16, 2015
- MHLW Council on Unapproved Drugs to Review Appropriateness of Humanitarian Trials, Notification Due Out November
October 15, 2015
- Chuikyo Subcommittee Roughly OKs Sakigake Pricing Premium, Yet No Agreement on Rate Raise
October 15, 2015
- Chuikyo Payer Reps Wary of Revising Foreign Price Adjustment Rule for Govt-Requested Drugs
October 15, 2015
- Chuikyo Tilting Toward Introduction of Re-Pricing for “Huge Seller” Drugs
October 15, 2015
- MOF Pitches Reimbursement Rate Cuts for OTC-Switched Ethical Drugs, Submission of Related Bills Eyed in 2017
October 13, 2015
- Takeuchi, Tokashiki Picked as Senior Vice Health Minister
October 13, 2015
- TPP Will Have No Impact on Japan’s Universal Care Scheme: Negotiator
October 9, 2015
- FY2013 Medical Expenditure Tops 40 Trillion Yen to Hit New High
October 9, 2015
- Chuikyo Payer and Doctor Reps Exchange Barbs on Spike in Generic Brand-Specified Scripts
October 8, 2015
- Abe’s New Cabinet Retains Shiozaki, Pro-Generics Kono Named as Administrative Reform Minister
October 8, 2015
ページ
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…